MedeliX
Start asking

elinzanetant

Lynkuet · ATC code G02CX07

Key facts
Active substance
elinzanetant
ATC code
G02CX07
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Lynkuet 60 mg soft capsules
Marketing authorisation holder
Bayer AG
Information as of
2026-10-27

Key facts

Elinzanetant is a non-hormonal neurokinin receptor antagonist. It is used to treat moderate to severe vasomotor symptoms (hot flushes) associated with menopause or caused by adjuvant endocrine therapy for breast cancer.

What it is used for

  • Moderate to severe vasomotor symptoms associated with menopause
  • Moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy related to breast cancer

Dosing

  • Recommended: 120 mg (two 60 mg capsules) once daily at bedtime
  • With moderate CYP3A4 inhibitors: 60 mg daily
  • Moderate to severe renal impairment (eGFR less than 60 mL/min/1.73 m²): 60 mg daily
  • Mild hepatic impairment: no change; moderate or severe: not recommended
  • Women over 65 years: no dose recommendation can be made
  • Swallow capsules whole with water, not with grapefruit (juice); assess benefit periodically

Contraindications

  • Hypersensitivity to the active substance or any excipient
  • Known or suspected pregnancy

Important warnings

  • Strong CYP3A4 inhibitors: concomitant use not recommended
  • Concomitant oestrogen HRT not studied and not recommended; local vaginal preparations can be used
  • With breast cancer treatments other than those studied, decide on individual benefit-risk
  • Contains sorbitol

Side effects

  • Menopause: most frequent headache (7.8%) and fatigue (5.0%)
  • Endocrine therapy setting: fatigue, somnolence, diarrhoea, depression, muscle spasm
  • Common: dizziness, abdominal pain, ALT increased

Interactions

  • Metabolised by CYP3A4; P-gp substrate
  • Itraconazole (strong CYP3A4 inhibitor) markedly increased exposure; strong inhibitors not recommended, reduce dose with moderate ones

Pregnancy and breastfeeding

  • Contraindicated in pregnancy; effective contraception, non-hormonal methods recommended
  • Breast-feeding: a risk to the infant cannot be excluded

Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

Package leaflet for patients →

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

Source: European Medicines Agency (EMA), product information

Brand names in 3 more European countries
Iceland
Lynkuet
Liechtenstein
Lynkuet
Norway
Lynkuet

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Lynkuet – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/lynkuet-epar-product-information_en.pdf

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.